tetano
Editor, Senior Moderator
N Engl J Med
. 2021 Oct 6.
doi: 10.1056/NEJMoa2114114. Online ahead of print.
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly[SUP] 1 [/SUP], Patrick Tang[SUP] 1 [/SUP], Mohammad R Hasan[SUP] 1 [/SUP], Sawsan AlMukdad[SUP] 1 [/SUP], Hadi M Yassine[SUP] 1 [/SUP], Fatiha M Benslimane[SUP] 1 [/SUP], Hebah A Al Khatib[SUP] 1 [/SUP], Peter Coyle[SUP] 1 [/SUP], Houssein H Ayoub[SUP] 1 [/SUP], Zaina Al Kanaani[SUP] 1 [/SUP], Einas Al Kuwari[SUP] 1 [/SUP], Andrew Jeremijenko[SUP] 1 [/SUP], Anvar H Kaleeckal[SUP] 1 [/SUP], Ali N Latif[SUP] 1 [/SUP], Riyazuddin M Shaik[SUP] 1 [/SUP], Hanan F Abdul Rahim[SUP] 1 [/SUP], Gheyath K Nasrallah[SUP] 1 [/SUP], Mohamed G Al Kuwari[SUP] 1 [/SUP], Hamad E Al Romaihi[SUP] 1 [/SUP], Adeel A Butt[SUP] 1 [/SUP], Mohamed H Al-Thani[SUP] 1 [/SUP], Abdullatif Al Khal[SUP] 1 [/SUP], Roberto Bertollini[SUP] 1 [/SUP], Laith J Abu-Raddad[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.
Methods: We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021.
Results: Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months.
Conclusions: BNT162b2-induced protection against SARS-COV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).
. 2021 Oct 6.
doi: 10.1056/NEJMoa2114114. Online ahead of print.
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly[SUP] 1 [/SUP], Patrick Tang[SUP] 1 [/SUP], Mohammad R Hasan[SUP] 1 [/SUP], Sawsan AlMukdad[SUP] 1 [/SUP], Hadi M Yassine[SUP] 1 [/SUP], Fatiha M Benslimane[SUP] 1 [/SUP], Hebah A Al Khatib[SUP] 1 [/SUP], Peter Coyle[SUP] 1 [/SUP], Houssein H Ayoub[SUP] 1 [/SUP], Zaina Al Kanaani[SUP] 1 [/SUP], Einas Al Kuwari[SUP] 1 [/SUP], Andrew Jeremijenko[SUP] 1 [/SUP], Anvar H Kaleeckal[SUP] 1 [/SUP], Ali N Latif[SUP] 1 [/SUP], Riyazuddin M Shaik[SUP] 1 [/SUP], Hanan F Abdul Rahim[SUP] 1 [/SUP], Gheyath K Nasrallah[SUP] 1 [/SUP], Mohamed G Al Kuwari[SUP] 1 [/SUP], Hamad E Al Romaihi[SUP] 1 [/SUP], Adeel A Butt[SUP] 1 [/SUP], Mohamed H Al-Thani[SUP] 1 [/SUP], Abdullatif Al Khal[SUP] 1 [/SUP], Roberto Bertollini[SUP] 1 [/SUP], Laith J Abu-Raddad[SUP] 1 [/SUP]
Affiliations
- PMID: 34614327
- DOI: 10.1056/NEJMoa2114114
Abstract
Background: Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.
Methods: We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021.
Results: Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months.
Conclusions: BNT162b2-induced protection against SARS-COV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).